Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

2023 State of Revenue Report highlights staffing challenges for pharma companies

By Brian Buntz | February 7, 2023

Pharmaceutical Worker At Work

[Image courtesy of Adobe Stock]

The software company Model N (NYSE:MODN) has released its fifth annual State of Revenue report that found many pharma companies are grappling with staffing and economic challenges. In particular, 92% of pharmaceutical firms reported difficulties hiring qualified personnel.

A number of pharma companies are cutting staff this year.

Almost half, 47%, of pharma execs believed outsourcing was a permanent need for business operations and to address the staffing shortfall. In particular, nearly all pharmaceutical executives (99%) plan to use Business Process Outsourcing (BPO) to support their business. About two-thirds consider BPO to play a “substantial” or “significant” role. Another 31% expect BPO to have a “moderate” role.

Regulatory compliance concerns

In addition to staffing concerns, the survey also reflected that pharma companies face significant regulatory compliance challenges affecting their revenue management programs. A total of 97% of executives said they were adapting their financial controls to deal with those hurdles.

A total of 38% said that increasing price transparency requirements would affect their revenue management programs. Nine of ten pharma execs reported concerns that data collected through price transparency reporting could hurt their operations. Of those, 34% said such state pricing transparency mandates were a major concern.

Inflation Reduction Act remains unpopular

Many pharma executives have balked at the pharma provisions of the Inflation Reduction Act. In an earnings call, Novartis CEO Vas Narasimhan said the industry might pursue legislative action to reduce the legislation’s impact on the pharma industry. Narasimhan is the incoming chairman of the PhRMA trade association.

The 2023 State of Revenue Report from Model N was conducted by research partner Dimensional Research. It surveyed more than 300 executives responsible for revenue management at large pharmaceutical, medtech, high-tech manufacturing and semiconductor companies.

A total of 84% of cross-industry executives surveyed deemed inflation to be the most significant impact on innovation.

In addition, seven out of ten executives across the survey agreed that their industry is losing billions as a result of poor revenue management practices such as ineffective pricing and quoting. All the executives surveyed reported a strong interest in pursuing data-driven technologies to improve revenue management.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE